CN100453125C - Non-viscous medical use liquid embolic agent - Google Patents
Non-viscous medical use liquid embolic agent Download PDFInfo
- Publication number
- CN100453125C CN100453125C CNB2006101456411A CN200610145641A CN100453125C CN 100453125 C CN100453125 C CN 100453125C CN B2006101456411 A CNB2006101456411 A CN B2006101456411A CN 200610145641 A CN200610145641 A CN 200610145641A CN 100453125 C CN100453125 C CN 100453125C
- Authority
- CN
- China
- Prior art keywords
- ethylene
- suppository
- vinyl alcohol
- copolymer
- developing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
Abstract
A non-adhesive liquid-state embolizing agent for treating cerebral arteriovenous malformation (AVM) and aneurysm is composed of the water-insoluble organic polymer soluble to organic solvent containing alcohol and the medical developer.
Description
Technical field
The present invention relates to a kind of medical use liquid compositions, particularly a kind of liquid embolizing agent that can be used as embolism materials use in the therapeutic treatment.
Background technology
In therapeutic treatment, transcatheter embolization is the important technology in the interventional therapy, also is one of three big technology of interventional radiology.It is that some artificial embolism materials controlledly are injected in the supply blood vessel of pathological changes or organ or in the lesion vessels, makes it to take place inaccessible, interrupts the blood confession, with the purpose that reaches control over bleeding, treatment vascular lesions, tumor and eliminate the diseased organ function.
Arteriovenous malformation of brain (brain AVM) and aneurysm are clinical the most common hemorrhagic apoplexys, epilepsy clonus, delayed ischemic neurological deficits easily take place and break hemorrhagely, and disability rate and case fatality rate are all very high, are difficult problems that perplexs endovascular neurosurgery for many years.Along with the continuous development of interventional therapeutic technique in the blood vessel, the application of vascular peg stay plug art in the middle of the above-mentioned two kinds of diseases of treatment more and more widely.This technology can provide function of nervous system to save best, best results, degree of safety maximum, the painful minimum treatment of wound from damage to patient, becomes the important component part in brain AVM and the aneurysm Comprehensive Treatment technology gradually.
At present, being used for the treatment of aneurysmal more common embolism materials is GDC (taking off property of electrolysis turn).United States Patent (USP) U.S.Pat.NO.6, explanation is exactly the use in embolotherapy of GDC and assistive device thereof in 537,293 and NO.6,527,790.The propeller of GDC adopts the microwelding technology with being connected of microcoils, turn is extremely soft, little to tumor wall pressure power, can adjust the position of turn repeatedly, behind position suitable, pusher connects the logical weak unidirectional current (0.5-2mA) of positive source, and the rustless steel that does not cover insulating barrier between platinum turn and pusher need not spur with regard to releasable turn promptly by electrolysis in aneurysm.But there is the unfavorable defective of matching in GDC, and thromboembolism not exclusively, easily break in low, the art of thrombosis rate hemorrhagely, cost an arm and a leg, the manufacturing process complexity is not a kind of ideal embolism materials.
The more common embolism materials that is used for the treatment of brain AVM is NBCA (α-cyanogen n-butyl acrylate).NBCA is a kind of cyanoacrylate liquid embolic material.United States Patent (USP) U.S.Pat.NO.6, explanation is exactly the liquid embolic material of cyanoacrylate in 476,069, is by formaldehyde and the corresponding synthetic polymer of alkyl cyanide acetas, again through the liquid monomer of hydrolysis distillation gained.Because the dual electrophilic effect of cyano group and carboxyl, make carbon atom be subjected to anion catalysis in the blood and polymerization rapidly, thereby play the effect of permanent thromboembolism.At present, embolism materials is of a great variety, and theoretically, the liquid embolic material can directly inject aneurysm tumor intracavity, can adapt to the aneurysm cavity of difformity and size fully, makes and does not stay any space between tumor wall and the embolism materials, thereby reach permanent thromboembolism.On the other hand, because easy operating can directly inject blood vessel by elongated microtubular, thereby relative other embolism materials of liquid embolic material are more satisfactory embolism materials.But still there is the shortcoming of " collophore " in existing NBCA embolism materials, promptly because it has adhesiveness, after injection, very easily microtubular is adhered to blood vessel wall, make troubles, in addition to operation technique, can emit heat in the time of monomer polymerization, also be a shortcoming of this embolism materials.
Summary of the invention
The purpose of this invention is to provide a kind of novel arteriovenous malformation of brain (brain AVM) and aneurysmal non-adhesive liquid embolizing agent of being used for the treatment of.
Non-viscous medical use liquid embolic agent of the present invention, combine by the water-insoluble organic polymer and the medical development agent that are dissolved in the organic solvent, the vinyl that contains 30%～50% mole percent in the described organic polymer, and the mass/volume percent of organic polymer in suppository is 3.0%～25%, the mass/volume percent of developing agent in suppository is 15%～40%, surplus is an organic solvent, and contain ethanol in the described organic solvent, ethanol is 5～35% in the percentage by volume of suppository.
Wherein, described organic polymer is to be selected from a kind of in cellulose acetate, polyvinyl acetate, cellulose acetate-butyrate, nitrocellulose, styrene-maleic acid copolymer and the ethylene-vinyl alcohol copolymer, is preferably ethylene-vinyl alcohol copolymer.
Wherein, also be added with a kind of in dimethyl sulfoxine and the acetone in the described organic solvent.
Wherein, described developing agent is to be selected from a kind of in tantalum powder, iohexol, barium sulfate and the bismuth oxide, be preferably tantalum powder or bismuth oxide, and particle size range is 1 μ m～30 μ m.
More specifically, non-viscous medical use liquid embolic agent of the present invention is formed by ethylene-vinyl alcohol copolymer, dimethyl sulfoxine and ethanol, developing agent tantalum powder or bismuth oxide powder mixes; Contents of ethylene in therein ethylene-ethenol copolymer is 35%～50% mole percent, and the mass/volume percent of described copolymer in suppository is 3.0%～25%; The mass/volume percent of developing agent in suppository is 15%～40%, and the particle size range of developing agent is 1 μ m-30 μ m, and ethanol is 5～35% in the percentage by volume of suppository.
Preferred, non-viscous medical use liquid embolic agent of the present invention, contents of ethylene in the described ethylene-vinyl alcohol copolymer is 30%～45% mole percent, the mass/volume percent of copolymer in suppository is 6%～20%, the mass/volume percent of developing agent in suppository is 20%～35%, ethanol is 5～30% in the percentage by volume of suppository, and the particle size range of developing agent is 1 μ m-10 μ m.
Preferred again, non-viscous medical use liquid embolic agent of the present invention, contents of ethylene in the described ethylene-vinyl alcohol copolymer is 33% mole percent, the mass/volume percent of copolymer in suppository is 6%～20%, the mass/volume percent of developing agent in suppository is 33%, and the particle size range of developing agent is 5 μ m.
The non-viscous medical use liquid embolic agent that another purpose of the present invention is to provide above-mentioned is in the application for preparing treatment brain AVM and aneurysmal embolism materials.
Adopt as above technical scheme, the present invention has selected suitable component for use and has passed through adjustment proportioning each other, make the non-adhesive liquid embolic material that obtains be suitable for fully using clinically, can directly inject the thromboembolism position, the difformity and the size that adapt to the thromboembolism position fully, make between blood vessel wall or aneurysm tumor wall and the embolism materials and do not stay any space, thereby reach the purpose of permanent thromboembolism; On the other hand, also make this liquid embolizing agent inject not collophore of blood vessel process, easy operating by elongated microtubular; For reducing to use the potential blood vessel toxicity of dimethyl sulfoxine, the present invention strengthens the ratio of copolymer and uses mixed solvent and reduce the use amount of dimethyl sulfoxine, tool acceptability when making it be applied to treat as far as possible.
The specific embodiment
The present invention is the liquid embolic material that a kind of non-adhesive will be provided.
In the liquid embolic material, at first need polymer is dissolved in organic solvent evenly.When the organic solution that contains polymer contacted with water-soluble solution, disperse was in aqueous solution soon for organic solvent, and polymer is then separated out and become solid and play the thromboembolism effect
For adapting to the clinical operation needs, also need to add developing agent in the embolism materials.Developing agent be a kind of can be used for life intravital, be easy to the material that the doctor carries out the not saturating X-ray of clinical monitoring, in operation process, under X-ray, play the effect of development.Developing agent can be water miscible also can be non-water-soluble, non-water-soluble developing agent commonly used has tantalum powder, bismuth oxide and barium sulfate etc., water miscible developing agent has iohexol etc.
In the liquid embolic material, the effect and the available scope of all kinds of material performances have:
Organic polymer (A): be insoluble to aqueous solution, have biocompatibility, a certain amount of human body that is used for can not produce harm to human body.Can be dissolved in B, form polymer solution, when polymer solution ran into aqueous solution, B was dissolved in the aqueous solution rapidly, and A separates out the formation precipitation gradually, thereby played the thromboembolism effect.Can select for use cellulose acetate, polyvinyl acetate, cellulose acetate-butyrate, nitrocellulose, polyurethane, polyacrylonitrile, styrene-maleic acid copolymer, ethylene-vinyl alcohol copolymer etc. to be insoluble to the polymer of aqueous solution.
Organic solvent (B): have the organic solvent of biocompatibility, can dissolve A, and can be dissolved in aqueous solution rapidly.Can select for use dimethyl sulfoxine, ethanol, acetone etc. to have the organic solvent that very easily is dissolved in aqueous solution of biocompatibility, also can be the mixed solvent of above-mentioned solvent.
Developing agent (C): in operation process, under X-ray, play the effect of development.Can select tantalum powder, iohexol, barium sulfate, bismuth oxide etc. for use.Bismuth oxide is not seen as yet before this and is used for brain AVM and aneurysmal treatment.
The present invention has optimized each component of non-adhesive liquid embolizing agent through a large amount of tests.At first, in the middle of the organic solvent, dimethyl sulfoxine and ethanol are more satisfactory solvents, dissolubility is very strong, and very easily water-soluble, after aqueous solution contacts, can be diffused into immediately in the solution, wherein reduce the use amount of dimethyl sulfoxine in the present invention's design as far as possible to reduce toxicity; The polymer aspect, optimal ethylene-ethenol copolymer, it is dissolved in dimethyl sulfoxine and ethanol mixed solvent, after aqueous solution contacts, separate out the precipitation the used time shorter, it is good to separate out precipitation strength, than being more suitable for embolotherapy, is more satisfactory selection.Consider development effect with and precipitation separated out the influence of time, preferred tantalum powder and bismuth oxide powder are developing agent.
Aspect each component ratio definite, on the one hand since the dimethyl sulfoxine organic solvent that uses its certain potential blood vessel toxicity is arranged, the invention is intended to the ratio by strengthening copolymer and use mixed solvent and reduce the use amount of dimethyl sulfoxine as far as possible; On the other hand, developing agent choose and appropriate consumption also needs special design not only to be convenient to operation but also to reduce consumption as far as possible.Therefore the component of non-adhesive liquid embolizing agent of the present invention is preferably ethylene-vinyl alcohol copolymer, dimethyl sulfoxine and ethanol mixed solvent, tantalum powder or iohexol powder.Learn through experiment, contents of ethylene in ethylene-vinyl alcohol copolymer is in 35%～50% (mole percent), the mass/volume percent of copolymer in suppository is 3%～25%, the mass/volume percent of developing agent in suppository is 15%～40%, the particle size range of developing agent is 1 μ m～30 μ m, the liquid embolizing agent of ethanol assembly in the percentage by volume of suppository is 5～35% scope all can be implemented in the present invention.
Further optimization experiment shows, each component ratio is preferably: the contents of ethylene in the ethylene-vinyl alcohol copolymer is 35%～45% (mole percent), the mass/volume percent of copolymer in suppository is 6%～20%, the mass/volume percent of developing agent in suppository is 20%～35%, the particle size range of developing agent is (1 μ m～10 μ m), and alcoholic acid percentage by volume is 5～30%.
Below with the composition of specific embodiment explanation non-adhesive liquid embolizing agent of the present invention, used reagent, raw material are the commercially available prod in the experiment.
Embodiment one
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, getting 2.0g ethylene-vinyl alcohol copolymer (contents of ethylene is 10%) then is dissolved in 100ml dimethyl sulfoxine and the ethanol mixed solvent (alcoholic acid amount is 5.0ml), after treating that polymer dissolves fully, pack in the ampoule bottle, stand-by.
Embodiment two
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, getting 3.0g ethylene-vinyl alcohol copolymer (contents of ethylene is 35%) then is dissolved in 100ml dimethyl sulfoxine and the ethanol mixed solvent (alcoholic acid amount is 35ml), after treating that polymer dissolves fully, pack in the ampoule bottle, stand-by.
Embodiment three
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, getting 5.0g ethylene-vinyl alcohol copolymer (contents of ethylene is 35%) then is dissolved in 100ml dimethyl sulfoxine and the ethanol mixed solvent (alcoholic acid amount is 13ml), after treating that polymer dissolves fully, pack in the ampoule bottle, stand-by.
Embodiment four
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, getting 6.0g ethylene-vinyl alcohol copolymer (contents of ethylene is 50%) then is dissolved in 100ml dimethyl sulfoxine and the ethanol mixed solvent (alcoholic acid amount is 30ml), after treating that polymer dissolves fully, pack in the ampoule bottle, stand-by.
Embodiment five
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, getting 10g ethylene-vinyl alcohol copolymer (contents of ethylene is 45%) then is dissolved in 100ml dimethyl sulfoxine and the ethanol mixed solvent (alcoholic acid amount is 10ml), after treating that polymer dissolves fully, pack in the ampoule bottle, stand-by.
Embodiment six
Ethylene-vinyl alcohol copolymer before use 100 ℃ the baking 5 hours, get 25g ethylene-vinyl alcohol copolymer (contents of ethylene is 40%) then and be dissolved in the 80g acetone, treat that polymer dissolves fully after, in the ampoule bottle of packing into, stand-by.
Embodiment seven
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, getting 20g ethylene-vinyl alcohol copolymer (contents of ethylene is 60%) then is dissolved in 100ml dimethyl sulfoxine and the ethanol mixed solvent (alcoholic acid amount is 15ml), after treating that polymer dissolves fully, pack in the ampoule bottle, stand-by.
Embodiment eight
Get 15g polyvinyl acetate (contents of ethylene is 20%) and be dissolved in the 85g dimethyl sulfoxine, treat that polymer dissolves fully after, in the ampoule bottle of packing into, stand-by.
Embodiment nine
Get the 20g cellulose acetate and be dissolved in the 80g acetone, treat that polymer dissolves fully after, in the ampoule bottle of packing into, stand-by.
By external simulation test, the effect of embolization of comparing embodiment one to embodiment nine, separate out precipitation used time and pliability.The external simulation test method:
Method one: get solution 0.1～0.5ml in the above-mentioned ampoule bottle with the syringe of 1ml, inject the normal saline under 37 ℃ or the room temperature, observe suppository solution and touch state behind the saline.Wherein becoming whippy bulk precipitation immediately, it is firm, intensive into meeting the requirements that precipitation becomes from outside to inside gradually.
Method two: use the device of mainly being made up of the thermostatic water tank of glass tubing (long 900mm, external diameter 80mm) and band water pump, thermostatic water tank provides 37 ℃ of isoperibols for glass tubing; The bead of 12g diameter 2mm is packed in the glass column of volume 10ml, and glass column places in the homothermic glass tubing, links by pvc pipe and normal saline bottle, and the vertical dimension of normal saline and glass column outlet is 150cm; Microtubular places in the glass column by the Y valve.With the flow rate regulation of normal saline is about 0.3ml/s, puts one 37 ℃ of constant temperature beakers below outflow end.With the gradation of 1ml syringe suppository is injected by microtubular, observe the precipitate dispersions situation of suppository in glass column, have or not precipitation to flow out via the outlet of glass column.Expected result is to have precipitation to separate out in the bead container, and can effectively clog the gap between the bead, and the current by bead are stopped, and simultaneously, does not have precipitation to go out from the upper and lower opening of bead container.
Experimental result sees table:
Comprehensive two kinds of external simulation test methods, the result of embodiment four and embodiment five is all more satisfactory, and all the other embodiment or precipitation perhaps go out the pipe difficulty out of order, are unsuitable for the microtubular injection.From above test as can be seen, contents of ethylene is at 35～50% o'clock, and polymer concentration is at 6～25% o'clock, and the state that forms suppository is more suitable, and operation also being easy to carry out.Wherein, strengthen when contents of ethylene too low (as embodiment one) can make the polymer hydrophilic, contents of ethylene too high (as embodiment seven) can make the polymer flexibility variation, is unfavorable for the microtubular injection; The mass percent of polymer in suppository too low (as embodiment one and embodiment two), what then form precipitates into Powdered, leakiness, be unfavorable for thromboembolism, mass percent too high (as embodiment six) can cause suppository viscosity too big, is unfavorable for the microtubular injection.By above experiment, point out out preferred suppository to form and be ethylene-vinyl alcohol copolymer, dimethyl sulfoxine, ethanol system, therein ethylene base content is 30%～45% (mole percent) more preferably 33%, the mass percent of copolymer in suppository is 6%～25%, more preferably 6～20%.
On the basis of above-mentioned optimization system, further determine developing agent and consumption and suitable particle diameter among the present invention by following experiment.
Embodiment ten
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, getting 6.0g ethylene-vinyl alcohol copolymer (contents of ethylene is 40%) then is dissolved in 100ml dimethyl sulfoxine and the ethanol mixed solvent (alcoholic acid amount is 10ml), after treating that polymer dissolves fully, add 5g tantalum powder (particle diameter is 20 μ m), shake up, pack in the ampoule bottle, it is stand-by to sterilize.
Embodiment 11
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, get 6.0g ethylene-vinyl alcohol copolymer (contents of ethylene is 40%) then and be dissolved in 100ml dimethyl sulfoxine and ethanol mixed solvent (alcoholic acid amount is 12ml), after treating that polymer dissolves fully, add 33.0g tantalum powder (particle diameter is 1 μ m), shake up, pack in the ampoule bottle, it is stand-by to sterilize.
Embodiment 12
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, get 8.0g ethylene-vinyl alcohol copolymer (contents of ethylene is 44%) then and be dissolved in 100ml dimethyl sulfoxine and ethanol mixed solvent (alcoholic acid amount is 10ml), after treating that polymer dissolves fully, add 40.0g bismuth oxide powder (particle diameter is 10 μ m), shake up, pack in the ampoule bottle, it is stand-by to sterilize.
Embodiment 13
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, get 15g ethylene-vinyl alcohol copolymer (contents of ethylene is 44%) then and be dissolved in 100ml dimethyl sulfoxine and ethanol mixed solvent (alcoholic acid amount is 5ml), after treating that polymer dissolves fully, add 21.0g tantalum powder (particle diameter is 5 μ m), shake up, pack in the ampoule bottle, it is stand-by to sterilize.
Embodiment 14
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, get 10g ethylene-vinyl alcohol copolymer (contents of ethylene is 38%) then and be dissolved in 100ml dimethyl sulfoxine and ethanol mixed solvent (alcoholic acid amount is 10ml), after treating that polymer dissolves fully, add 29.5g iohexol powder, after treating that iohexol dissolves fully, shake up, in the ampoule bottle of packing into, it is stand-by to sterilize.
Embodiment 15
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, getting 10g ethylene-vinyl alcohol copolymer (contents of ethylene is 38%) then is dissolved in 100ml dimethyl sulfoxine and the ethanol mixed solvent (alcoholic acid amount is 25ml), after treating that polymer dissolves fully, add 24.0g tantalum powder (particle diameter is 35 μ m), pack in the ampoule bottle, it is stand-by to sterilize.
Embodiment 16
Ethylene-vinyl alcohol copolymer is before use 100 ℃ of bakings 5 hours, getting 15g ethylene-vinyl alcohol copolymer (contents of ethylene is 38%) then is dissolved in the 85g dimethyl sulfoxine, after treating that polymer dissolves fully, add 12.8g tantalum powder (particle diameter is 30 μ m), shake up, pack in the ampoule bottle, it is stand-by to sterilize
Determine the consumption of developing agent of the present invention and suitable particle diameter thereof by zoopery.
Animal experiment method:
This experiment is main with non-adhesive liquid embolizing agent treatment arteriovenous malformation of brain (brain AVM), further determine the proportioning of each component of the embolism materials of thromboembolism formation time, formation temperature optimum clinical manipulation by zoopery, and the thromboembolism of observing embolism materials is permanent, the inflammatory reaction degree.
Method: the non-adhesive liquid embolizing agent with embodiment ten to embodiment 16 carries out blood vessel embolism to the pig of the six nose heave 20～25kg of being respectively.At first set up the AVM model, observe the modelling situation by left side ascending pharyngeal artery radiography.Conventional common carotid artery radiography before the art, the situation of observing model.Insert guiding catheter 1cm place to the ascending pharyngeal artery opening of left side, guiding catheter connects the Y valve, inserts microtubular through the Y valve.Microtubular puts in place after (left side ascending pharyngeal artery near strange net place), uses the 1ml syringe and injects with the speed of 0.02ml/s, until the complete thromboembolism of strange net.
Experimental applications non-adhesive liquid embolizing agent has carried out thromboembolism to 6 boss pig RMB, and the development effect of embodiment 11 and embodiment 12 is more satisfactory.The amount of developing agent is (as embodiment ten) or graininess developer particle too big (as embodiment 16) very little, can cause development effect discontinuous, is unfavorable for clinical practice; The amount that strengthens developing agent can make the development effect enhancing certainly, and still, the developing agent consumption strengthens, and has increased cost on the one hand, makes troubles also on the other hand the use of suppository, so the developing agent consumption of this experiment prompting use 20～35% is comparatively appropriate.As for developing agent, iohexol can be dissolved in the polymeric system, and development effect is also relatively good, but dissolution velocity is slower, and the precipitation speed of separating out is also slower; Tantalum powder particles particle diameter can be evenly dispersed in the middle of the system when 1～10 μ m very much, has good development effect.
Also observe in the experiment, the strange net of all thromboembolisms or ascending pharyngeal artery all do not show logical again.In the thromboembolism process, owing to inject excessive velocities during operation technique and cause excessively backflowing and take place the welded tube, plugging and collophore phenomenon all do not take place in all the other except that 1 example.X-ray opaque behind the adding tantalum powder, perspective is developed well with plain film, and the microtubular wall does not have suppository and sticks, and the plugging phenomenon does not take place.
As non-adhesive liquid embolic material, it is good that the non-adhesive liquid embolizing agent has the thromboembolism controllability, easily judges the starting point and the destination node of thromboembolism, the AVM animal model is had the stability of thromboembolism, and good biocompatibility does not have teratogenesis in a short time and takes place, and application safety, not collophore.
Simultaneously, this experimental result shows that the suppository that preferred ingredients of the present invention and proportioning obtain can be applied to the treatment of brain AVM, has safely, nontoxic as embolism materials, and injectable, easy to operate does not stop up, the characteristics of adhesion microtubular.
In addition, suppository of the present invention directly plays a role in lesion, does not involve other position, is free from side effects.If solvent for use is a dimethyl sulfoxine in the suppository, it has certain potential blood vessel toxicity, the present invention by strengthening copolymer ratio and use mixed solvent and reduce the use amount of dimethyl sulfoxine as far as possible, and slowly inject when noting using, alleviate the potential blood vessel toxicity of dimethyl sulfoxine, zoopery has confirmed the present invention program's acceptability as far as possible.
Claims (4)
1, a kind of non-viscous medical use liquid embolic agent is characterized in that, is formed by ethylene-vinyl alcohol copolymer, dimethyl sulfoxine and ethanol and developing agent tantalum powder or bismuth oxide powder mixes; Contents of ethylene in therein ethylene-ethenol copolymer is 35%～50% mole percent, and the mass/volume percent of described copolymer in suppository is 3.0%～25%; The mass/volume percent of developing agent in suppository is 15%～40%, and the particle size range of developing agent is 1 μ m-30 μ m, and ethanol is 5～35% in the percentage by volume of suppository.
2, non-viscous medical use liquid embolic agent according to claim 1 is characterized in that, the contents of ethylene in the described ethylene-vinyl alcohol copolymer is 44% mole percent, and the mass/volume percent of copolymer in suppository is 8%; Developing agent is a bismuth oxide, and the mass/volume percent in suppository is 40%, and particle diameter is 10 μ m; Ethanol is 10% in the percentage by volume of suppository.
3, non-viscous medical use liquid embolic agent according to claim 1 is characterized in that, the contents of ethylene in the described ethylene-vinyl alcohol copolymer is 40% mole percent, and the mass/volume percent of copolymer in suppository is 6%; Developing agent is the tantalum powder, and particle diameter is 1 μ m, and the mass/volume percent in suppository is 33%; Ethanol is 12% in the percentage by volume of suppository.
4, claim 1 or 2 or 3 described non-viscous medical use liquid embolic agents are in the application of preparation treatment brain AVM and aneurysmal embolism materials.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101456411A CN100453125C (en) | 2006-11-22 | 2006-11-22 | Non-viscous medical use liquid embolic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101456411A CN100453125C (en) | 2006-11-22 | 2006-11-22 | Non-viscous medical use liquid embolic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1947803A CN1947803A (en) | 2007-04-18 |
| CN100453125C true CN100453125C (en) | 2009-01-21 |
Family
ID=38017492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101456411A Active CN100453125C (en) | 2006-11-22 | 2006-11-22 | Non-viscous medical use liquid embolic agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100453125C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101513542B (en) * | 2009-03-27 | 2012-08-15 | 山东大正医疗器械股份有限公司 | Method for preparing iodic liquid embolic agent capable of self-developing for long-time |
| CN101822635B (en) * | 2010-04-15 | 2011-12-14 | 中山大学 | Novel in situ liquid crystal vascular embolization agent |
| CN108079366A (en) * | 2017-01-24 | 2018-05-29 | 珠海神平医疗科技有限公司 | A kind of liquid embolic material and preparation method thereof |
| CN107875436B (en) * | 2017-11-10 | 2020-02-18 | 杭州华微医疗科技有限公司 | Sodium bicarbonate powder-loaded liquid embolic agent composition and application thereof |
| CN107754007A (en) * | 2017-12-06 | 2018-03-06 | 华威（深圳）医疗器械有限责任公司 | The carrier compositions and preparation method of a kind of nucleic, liquid embolizing agent and application method and nucleic mixture |
| US11801058B2 (en) * | 2021-03-04 | 2023-10-31 | Accumedical Beijing Ltd. | Liquid embolic compositions |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1015229B (en) * | 1986-10-13 | 1992-01-01 | 西安化工研究所 | Process of preparation for blood vessel thrombotic agent (th glue) |
| CN1079642C (en) * | 1995-07-27 | 2002-02-27 | 微治疗公司 | Novel embolizing compositions |
| CN1634119A (en) * | 2004-11-16 | 2005-07-06 | 南京大学 | Liquid embolism agent for intracranial aneurysm and its preparing process |
-
2006
- 2006-11-22 CN CNB2006101456411A patent/CN100453125C/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1015229B (en) * | 1986-10-13 | 1992-01-01 | 西安化工研究所 | Process of preparation for blood vessel thrombotic agent (th glue) |
| CN1079642C (en) * | 1995-07-27 | 2002-02-27 | 微治疗公司 | Novel embolizing compositions |
| CN1634119A (en) * | 2004-11-16 | 2005-07-06 | 南京大学 | Liquid embolism agent for intracranial aneurysm and its preparing process |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1947803A (en) | 2007-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3356447B2 (en) | Vascular lesion embolic material composed of dried polymer gel | |
| CN100453125C (en) | Non-viscous medical use liquid embolic agent | |
| US7666339B2 (en) | Hydrogel string medical device | |
| JP2003502131A (en) | Method for embolizing a vascular site using an embolizing composition | |
| JP2001509133A (en) | Compositions for use in occluded vessels | |
| Lord et al. | Advancements in the development on new liquid embolic agents for use in therapeutic embolisation | |
| CN107899064A (en) | A kind of medicine-carried and the preparation method and its usage for having the liquid embolizing agent of developability concurrently | |
| CA2293583A1 (en) | Contoured syringe and novel luer hub and methods for embolizing blood vessels | |
| US11291748B2 (en) | Embolism material for blood vessel, preparation method therefor and use thereof in preparation of drugs | |
| JP2005530815A (en) | Novel high viscosity occlusive composition containing prepolymer | |
| CN105462142A (en) | Thermo-sensitive type interpenetrating polymer network hydrogel material and preparation method and application thereof | |
| JPH0656676A (en) | Suspension for blood vessel embolization | |
| CN104130348A (en) | Temperature-sensitive polymer, in-situ gelation temperature-sensitive liquid embolic material and preparation method thereof | |
| CN106102601B (en) | Mixing syringe | |
| CN108434580B (en) | Releasable microcatheter with double-coating at head end | |
| JP2000517298A (en) | A novel method for embolizing luminal sites with an embolic composition containing dimethyl sulfoxide | |
| JPH0557014A (en) | Polymer solution for forming artificial embolus | |
| WO2018137633A1 (en) | Liquid embolic material and preparation method therefor | |
| JP2007037989A (en) | Pva particle for blood vessel-temporarily embolizing agent, method for producing the same, and blood vessel-temporarily embolizing agent | |
| JP3103368B2 (en) | Embolization material for vascular lesions | |
| JPH05208917A (en) | Blood vessel embolization agent | |
| JP7430904B2 (en) | Method for producing embolic substances, embolic substances and kits for producing embolic substances | |
| CN107875436A (en) | A kind of composition of liquid embolizing agent for loading sodium bicarbonate powder and application thereof | |
| US8691246B2 (en) | Composition for forming a temporary intestinal occlusion in a mammal | |
| Park et al. | An arteriovenous malformation model for testing liquid embolic materials. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 250100 Shandong high tech Development Zone, Ji'nan Patentee after: Shandong saikesaisi Biological Technology Co., Ltd. Address before: 250100 Shandong high tech Development Zone, Ji''nan Patentee before: Shandong Success Pharmaceutical Technology Co., Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 250100 No. 2222 Pioneer Road, Jinan High-tech Development Zone, Shandong Province Patentee after: SEXES BIOLOGICAL TECHNOLOGY CO., LTD. Address before: 250100 Development Intersection of Jinan High-tech Development Zone in Shandong Province Patentee before: Shandong saikesaisi Biological Technology Co., Ltd. |